45 Sidney Street
Cambridge, MA 02139
United States
617 374 7580
https://www.blueprintmedicines.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 655
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Ms. Kathryn Haviland | President, CEO & Director | 1,17M | S.O. | 1976 |
Mr. Alexis A. Borisy A.M. | Co-Founder & Director | 50k | S.O. | 1972 |
Mr. Michael Landsittel | Chief Financial Officer | 785,36k | S.O. | 1972 |
Ms. Christina Rossi | Chief Operating Officer | 875,22k | S.O. | 1977 |
Ms. Tracey L. McCain Esq. | Executive VP, Chief Legal & Compliance Officer and Secretary | 764,9k | S.O. | 1968 |
Dr. Fouad Namouni M.D. | President of Research & Development | 916,4k | S.O. | 1969 |
Ms. Ariel Hurley | Senior VP, Finance & Principal Accounting Officer | S.O. | S.O. | 1974 |
Dr. Christopher K. Murray Ph.D. | Senior VP of Technical Operations and Chief Technical Operations & Quality Officer | 338,37k | S.O. | 1964 |
Dr. Percy H. Carter M.B.A., Ph.D. | Chief Scientific Officer | 761,15k | S.O. | 1971 |
Jenna Cohen | Senior Director & Head of Investor Relations | S.O. | S.O. | S.O. |
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
L’ISS Governance QualityScore de Blueprint Medicines Corporation en date du 1 mars 2024 est 6. Les scores principaux sont Audit : 2; Société : 8; Droits des actionnaires : 7; Compensation : 6.